Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 3.2% – Here’s What Happened

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price traded down 3.2% during trading on Tuesday . The company traded as low as $0.37 and last traded at $0.39. 45,372,542 shares were traded during trading, an increase of 52% from the average session volume of 29,892,227 shares. The stock had previously closed at $0.40.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Tonix Pharmaceuticals in a research note on Monday. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Price Performance

The firm has a market capitalization of $72.01 million, a P/E ratio of -0.01 and a beta of 2.23. The company has a fifty day moving average of $0.21 and a 200 day moving average of $0.41. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Sell-side analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.